CCR2 and glioma: Moreover, genetic and pharmacologic inhibition of CCR2 reduces the presence of these CD45+, CD11b+, Ly6Chi, Ly6G- cells in the TME, promotes sequestration of the cells in the bone marrow, and unmasks an effect of an immune checkpoint inhibitor to slow glioma progression (28).